First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.

Curr Oncol · 2022 · PMC9600684 · PMID 36290852

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A post hoc analysis of KEYNOTE-240 showed a trend toward a greater efficacy benefit in the Asian subpopulation versus the overall cohort [ 53 ], consistent with the significant improvements in the OS, PFS, and ORR observed with pembrolizumab versus placebo in the KEYNOTE-394 study in Asian patients [ 29 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.